NCT00044759已完成3 期
A Randomized, Open-Label, Multi-Center, Comparative Study of the Efficacy and Safety of Piperacillin/Tazobactam to Cefepime for the Empiric Treatment of Neutropenic Fever in Patients With a Hematologic Malignancy or Lymphoma
Wyeth is now a wholly owned subsidiary of Pfizer36 个研究点 分布在 2 个国家开始时间: 2002年9月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 试验地点
- 36
研究概览
简要总结
To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hospitalized male and female patients, 18 years of age or older
- •Patients who have leukemia (acute lymphocytic leukemia [ALL], acute myelogenous leukemia [AML], chronic lymphocytic leukemia [CLL], chronic myelogenous leukemia [CML]), that is newly diagnosed, who have had initial induction, re-induction, or intensification chemotherapy or who have had a bone marrow (allogenic, syngeneic, or autologous) or peripheral blood stem-cell transplant OR Patients with lymphoma, Hodgkin's disease, multiple myeloma, myelodysplastic syndrome or myelodysplasia (refractory anemia [RA], refractory anemia with ringed sideroblasts [RARS], refractory anemia with excess blasts [RAEB], refractory anemia with excess blasts in transformation to leukemia [RAEB-T], or chronic myelomonocytic leukemia [CMML].
- •Fever, defined as an oral temperature of ≥ 37.9°C /100.2°F, a rectal temperature ≥ 38.4°C /101.4°F, or a tympanic temperature ≥ 38°C /100.4°F
排除标准
- •The presence of any clinically acute or chronic disease or condition that, in the opinion of the investigator, may interfere with the patient's ability to safely comply with the conditions of the protocol, or could preclude the evaluation of the patient's response or could make the completion of the therapy unlikely
- •Neutropenia associated with syndromes that are not associated with a high risk of bacterial infection (eg. chronic benign neutropenia or Kostmann's syndrome)
- •Neutropenia due to primary bone marrow failure
研究者
研究点 (36)
Loading locations...
相似试验
已完成
3 期
Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas AeruginosaPseudomonas Aeruginosa InfectionNCT01577368Fundación Pública Andaluza para la gestión de la Investigación en Sevilla76
进行中（未招募）
不适用
Eficacia y seguridad de Piperacilina/Tazobactam administrada en perfusión continua versus infusión intermitente en pacientes con infección complicada o nosocomial con sospecha o aislamiento de Pseudomonas aeruginosa.infecciones complicadas o de origen nosocomial con sospecha o aislamiento de Pseudomonas aeruginosaMedDRA version: 13Level: LLTClassification code 10021860Term: Infección por Pseudomonas aeruginosaEUCTR2010-024606-34-ESMª Victoria Gil Navarro
已完成
不适用
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology UnitsGram-Positive Bacterial InfectionsEscherichia Coli InfectionsKlebsiella InfectionsNCT00167999Wyeth is now a wholly owned subsidiary of Pfizer200
已完成
1 期
Pharmacokinetics and Safety of Piperacillin-tazobactam in NeonatesSepsisNCT00873327Phillip Brian Smith32
已完成
3 期
Ertapenem Sodium vs. Piperacillin/Tazobactam in the Treatment of Complicated Intra-Abdominal Infections (0826-037)Complicated Intra-Abdominal InfectionsNCT00389987Merck Sharp & Dohme LLC300